financetom
Business
financetom
/
Business
/
Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Listerine And Tylenol Maker Kenvue's Q3 Earnings: Revenue Miss On Weak Skin Health And Beauty Sales
Nov 9, 2024 12:19 PM

Consumer health company Kenvue Inc. ( KVUE )  reported third-quarter sales of $3.89 billion, down 0.4% year-over-year (up 0.9% organically), slightly below the consensus of $3.93 billion.

Kenvue’s some of the iconic brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol.

Also Read: Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?

Value realization was driven by a combination of carry-over pricing and price actions taken this year. The volume decline was driven primarily by Skin Health and Beauty and Self Care, partially offset by growth in Essential Health.

Adjusted gross profit margin expanded 130 basis points to 60.7% from 59.4% in the prior year, reflecting productivity gains attributable to global supply chain efficiency initiatives and benefits from value realization.

Third quarter adjusted operating income margin was 22.1% vs 23.3% in the prior year.

The self-care segment recorded $1.63 billion in net sales, up 0.7% year over year. The skin health and beauty segment recorded a 4.2% drop in second-quarter net sales to $1.07 billion. Essential Health segment sales increased around 1.6% to $1.20 billion.

“During the third quarter, we continued to drive strong productivity and realize efficiency benefits from Our Vue Forward, which we are reinvesting behind our iconic brands to unleash the full potential of our business and fulfill our commitment to create long-term shareholder value,” said Thibaut Mongon, Chief Executive Officer. “This reinvestment is enabling us to continue to drive share gains in Self Care, deliver broad-based growth across the Essential Health categories, and build the right foundation in Skin Health and Beauty, where we are seeing early signs of recovery. 

Guidance: Kenvue ( KVUE ) expects 2024 net sales growth and organic growth toward the low end of its outlook of 1.0%-3.0% and 2.0%-4.0%, respectively.

The consumer health giant reaffirms 2024 adjusted EPS of $1.10-$1.20 versus consensus of $1.14

Price Action: KVUE stock is up 3.44% at $23.28 at the last check on Thursday.

Read Next:

Barrick Gold Misses Earnings: Reports Lower Gold Sales And Copper Output

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blockfusion, Owner-Operator of a Strategically Located Clean Energy-Powered Data Center, to Go Public via Business Combination with Blue Acquisition Corp.
Blockfusion, Owner-Operator of a Strategically Located Clean Energy-Powered Data Center, to Go Public via Business Combination with Blue Acquisition Corp.
Nov 19, 2025
The surge in demand for HPC and AI compute is driving demand for data center capacity across the industry. Blockfusion's Niagara Facility has become a sought-after location for customers pursuing high-density HPC/AI deployments. Blockfusion is responding to this demand by upgrading and expanding an already powered and operational facility into a next-generation data center built for GPU-driven workloads. Blockfusion's owned and...
Kootenay Silver Reports First Assays from Ongoing Drilling at Columba Project in Mexico
Kootenay Silver Reports First Assays from Ongoing Drilling at Columba Project in Mexico
Nov 19, 2025
08:40 AM EST, 11/19/2025 (MT Newswires) -- Kootenay Silver ( KOOYF ) released Wednesday assays from the first seven holes of the ongoing 50,000-meter drill program at the Columba silver project in Mexico. The company said drilling identified porphyry style gold mineralization along the I vein. Highlights include 101 meters of 0.18 grams per tonne gold and 10 g/t silver,...
Moderna to complete US mRNA manufacturing network with $140 million investment
Moderna to complete US mRNA manufacturing network with $140 million investment
Nov 19, 2025
Nov 19 (Reuters) - Moderna ( MRNA ) said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network. The Cambridge-based company plans to invest more than $140 million to add the final manufacturing step to its existing facility in Massachusetts. The move...
Progressive October Net Income Rises
Progressive October Net Income Rises
Nov 19, 2025
08:40 AM EST, 11/19/2025 (MT Newswires) -- Progressive (PGR) on Wednesday reported October net income of $1.44 per share, up from $0.69 a year earlier. Net premiums earned in October were $7.08 billion, up from $6.39 billion a year earlier. Total companywide policies in force were 38.4 million, up from 34.4 million a year earlier. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved